AMI in Biological Technology

Seambiotic USA and NASA Glenn Research Center Signed Agreement for Large Scale Microalgae Process Optimization

...pace Act Agreement, NASA is partnering with Seambiotic USA to model growth processes for microalgae for use as aviation biofuel feedstock," said Prof. ami Ben-Amotz, Chief Scientific Adviser to Seambiotic. "The goal of the Agreement is to make use of NASA's expertise in large scale computational modeling...

OrbusNeich's Genous(TM) Bio-engineered R stent(TM) Demonstrates Impressive Results in Higher Risk Patients

...ient (0.2%) having a stent thrombosis. Suryapranata commented, "This rate is impressively low given the highly thrombotic environment associated with ami patients." Longer term follow up is ongoing. Juan F Granada, MD, medical director of the Skirball Center for Cardiovascular Research at Columbi...

Amorcyte Reports Phase I Results of AMR-001 to Improve Recovery From Severe Heart Attack at ACC Annual Scientific Session

...s completed Phase I clinical trials demonstrating feasibility, safety and biologic activity at a threshold dose. This is the first stem cell trial in ami ever conducted that has prospectively established a significant relationship between dose and effect. Amorcyte has partnered with Progenitor Cell The...

BioComp Pharma Launches First Generic Drug for Tindamax(R)

...oniasis, the intestinal infections giardiasis and intestinal amebiasis and amebic liver abscess. Media Contact: Cohn & Wolfe Ms. ami Shah (212) 537-8048 ami.shah@cohnwolfe.com (1) Saving Money on Prescription Drugs. U.S. Food and Drug Administration. Accessed at:...

LightLab Imaging Leads Global Advancement of Intracoronary Imaging

...htLab by deploying its M2 and M2x OCT imaging systems in critically important clinical studies. All OCT images acquired in the groundbreaking Horizons ami OCT data study, presented at the 2008 American Heart Association Congress, were generated using LightLab Imaging OCT systems. At TCT in October, Ligh...

Alfred Mann Foundation for Biomedical Engineering Launches New Web Site Designed to Help University Researchers Bring Biomedical Advances to Market

...., with an emphasis toward researchers involved in this space. "The ami concept has drawn a phenomenal response, both nationally and internationall...ses researchers' frequently asked questions and provides an overview of the ami selection and creation process." About Alfred Mann Alfred Mann'...

MGuard(TM), InspireMD's Novel Coronary Stent System, was Celebrated by World Leading Interventional Cardiologists at the Transcatheter Cardiovascular Therapeutics (TCT) in Washington DC, USA, October 12-17 2008

...oach to Treating Thrombus Containing Lesions (ACS, ami and SVG)" was met with great enthusiasm and excite...t the MGuard(TM) at their local hospitals for ACS, ami and SVG procedures claiming they had many patients...oach to Treating Thrombus Containing Lesions (ACS, ami and SVG)" was a great sensation. The meeting room ...

Nile Therapeutics Announces Positive Interim Data from Phase 2a Study of CD-NP in Patients with Heart Failure

...on of renal damage subsequent to cardiac surgery. We expect to initiate a Phase 2b study in patients with heart failure in 2009 and a Phase 2 study in ami patients. About Nile Therapeutics Nile Therapeutics, Inc. is a clinical-stage biopharmaceutical company that develops innovative products for the ...

Roche and Response Biomedical Corporation Aim to Reduce 'Vein-to-Brain' Time with New Point-of-Care Cardiac Tests

...ng. Guidelines from the American College of Cardiology and the American Heart Association require or recommend a patient presenting with a potential ami (acute myocardial infarction, or heart attack) be diagnosed within 60 minutes, and preferably within 30 minutes. "One of the advantages of this syst...

Angiotech announces results for the fourth quarter ended December 31, 2007

...") on March 23, 2006. Because of the timing of the ami acquisition, our operating results for the twelve ... rate note refinancing. n. Includes write off of ami tax receivable and write off of certain capit...nization costs related to the integration of ami (849) - Non-recurri...

Supportive devices or unnecessary surveillance?

...proaching world of ambient intelligence. In the ami vision, ubiquitous computing, communications and interfaces converge and adapt to the user. ami promises greater user-friendliness in an environme... way. While most stakeholders paint the promise of ami in sunny colours, there is a dark side to...

Athersys and Angiotech announce authorization of Phase I intramyocardial stem cell U.S. clinical trial in acute myocardial infarction

...reement in May 2006 to co-develop and commercialize MultiStem(R), Athersys' non-embryonic stem cell platform technology, for use in the indications of ami and peripheral vascular disease. Upon completion of the Phase I trial, Angiotech will assume lead responsibility for further clinical development. Ang...

Angiotech announces preliminary third quarter financial results and updates fiscal 2007 outlook

...to be between $42 million and $44 million. - Our full year 2007 outlook for revenue derived from sales of medical products obtained from ami is modestly lower as compared to our original expectations as a result of our decision to de-emphasize or discontinue certain product lines ...